SARS-CoV-2 infection in patients with autoimmune hepatitis

Back to overview

The manuscript on COVID-19 in patients with autoimmune liver diseases, based on data from the R-LIVER COVID-19 registry and in cooperation with the EASL and international COVID-19 registry, was recently accepted for publication by the Journal of Hepatology.

AIH patients represented the largest disease group and therefore this study focused on AIH. The results confirm that only older age and the degree of liver cirrhosis are risk factors for a severe course of COVID-19, but not immunosuppressive treatment of AIH. The second ERN-driven COVID-19 publication, the patient-oriented survey on COVID-19 being distributed by our patient representatives, is currently under review at the UEG journal.